BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28249824)

  • 1. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
    Yang J; Zhang R; Radford DC; Kopeček J
    J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
    Zhang L; Zhang R; Yang J; Wang J; Kopeček J
    J Control Release; 2016 Aug; 235():306-318. PubMed ID: 27266365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
    Li L; Yang J; Wang J; Kopeček J
    ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
    Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
    Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
    Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
    Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
    Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
    Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
    Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
    Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
    Chu YW; Polson A
    Future Oncol; 2013 Mar; 9(3):355-68. PubMed ID: 23469971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
    Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
    Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
    Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
    Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.